Axogen, Inc. (AXGN) stock

AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 11/30144% above fair value

$55.93+0.53 (+0.96%)

Close on Nov 13, 2026Market cap $3.34BP/E –Yield –

Axogen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Axogen's ebitda for the twelve months ending Sep 30, 2026 was -$7.39M, down 169.7% year over year. For fiscal 2025 it was -$1.19M, down 137.4% from the year before. The highest annual figure on record is $3.18M in fiscal 2024.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$1.19M	-137.4%
FY2024	Dec 31, 2024	$3.18M	–
FY2023	Dec 31, 2023	-$17.24M	–
FY2022	Dec 31, 2022	-$26.88M	–
FY2021	Dec 31, 2021	-$22.67M	–
FY2020	Dec 31, 2020	-$21.65M	–
FY2014	Dec 31, 2014	-$9.65M	–
FY2013	Dec 31, 2013	-$9.51M	–
FY2012	Dec 31, 2012	-$7.61M	–
FY2011	Dec 31, 2011	-$6.70M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$2.53M	-28.8%
Q2 FY2026	Jun 30, 2026	-$549.00K	-116.5%
Q1 FY2026	Mar 31, 2026	-$1.23M	-1932.8%
Q4 FY2025	Dec 31, 2025	-$8.14M	-322.8%
Q3 FY2025	Sep 30, 2025	$3.55M	+165.6%
Q2 FY2025	Jun 30, 2025	$3.33M	+170.9%
Q1 FY2025	Mar 31, 2025	$67.00K	–
Q4 FY2024	Dec 31, 2024	$3.65M	–
Q3 FY2024	Sep 30, 2024	$1.34M	–
Q2 FY2024	Jun 30, 2024	$1.23M	–
Q1 FY2024	Mar 31, 2024	-$3.04M	–
Q4 FY2023	Dec 31, 2023	-$1.64M	–
Q3 FY2023	Sep 30, 2023	-$2.87M	–
Q2 FY2023	Jun 30, 2023	-$6.11M	–
Q1 FY2023	Mar 31, 2023	-$6.63M	–
Q4 FY2022	Dec 31, 2022	-$4.96M	–
Q3 FY2022	Sep 30, 2022	-$4.09M	–
Q2 FY2022	Jun 30, 2022	-$7.21M	–
Q1 FY2022	Mar 31, 2022	-$10.62M	–
Q4 FY2021	Dec 31, 2021	-$4.67M	–
Q3 FY2021	Sep 30, 2021	-$6.04M	–
Q2 FY2021	Jun 30, 2021	-$6.52M	–
Q1 FY2021	Mar 31, 2021	-$5.45M	–